BTIG Downgrades Zimmer Biomet to Neutral Amid Growth Concerns

BTIG has downgraded Zimmer Biomet (ZBH) from Buy to Neutral, while simultaneously withdrawing its previous price target of $112. The downgrade follows a challenging period for the medical device company, whose shares have declined by 14.8% in fiscal 2025 despite efforts to improve profitability. Analysts noted that the recently launched "Magnificent 7" product line has failed to drive the expected acceleration in organic growth. Furthermore, BTIG highlighted concerns over a limited product cycle for fiscal 2026, suggesting restricted upside potential in the near term. Commercialization of the company's new autonomous robotics products is also delayed, with expectations pushed back to late 2027 or early 2028. This shift in rating reflects a cautious stance on the company's ability to navigate structural growth challenges and deliver immediate catalysts for investors.

Sources:Financial Modeling Prepinvesting.comgurufocus.commarketscreener.combenzinga.comtipranks.commarketbeat.comstreetinsider.com